B+
Bull case
25%
Probability
Target price
$108.00
+29.0% vs current
ZBH
Zimmer BiometDNYSE / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$101.00
+20.6% vs current
B-
Bear case
25%
Probability
Target price
$86.00
+2.7% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+67.3
Score
AI commentary
Primary evidence is real and recent, but the forward setup remains balanced rather than strongly bullish: 2026 guidance is positive yet modest, capital return is supportive, and the next major proof point is April 28, 2026. Given high coverage, only moderate evidence quality, and a loose peer set, this should remain a tentative monitoring memo rather than a standard-conviction call.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-28eventQ1 2026 earnings and guide checkMedium impact
Zimmer Biomet said on April 9, 2026 that it will release first-quarter 2026 results on April 28, 2026, with the main debate centered on whether the U.S. sales-model transition is containing disruption and whether full-year 2026 guidance remains intact [#IR-2026-04-09] [#8-K-2026-02-10].
2026-09-30catalystROSA Knee with OptimiZe and broader innovation cycleMedium impact
The February 10, 2026 results release highlighted FDA clearance for ROSA Knee with OptimiZe and cited a new-product cycle behind two consecutive quarters of mid-single-digit organic growth; the remaining question is whether that innovation converts into sustained share gains through 2026 [#8-K-2026-02-10].
2026-12-31catalystOngoing share repurchase supportMedium impact
The board approved a new $1.5 billion repurchase authorization on February 9, 2026 after $250 million of buybacks in Q4 2025, which should help downside support even if operating upside stays modest [#8-K-2026-02-10].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology